Does resistance to apoptosis affect clinical response to antitumor drugs?

Drug Resistance Updates

Volumn 4, Issue 2, 2001, Pages 129-131

  Borst, Piet ^a   Borst, Jannie ^b   Smets, Lou A ^c  

^a Division of Molecular Biology   (Netherlands)

^b Division of Cellular Biochemistry   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; PROTEIN BCL 2; PROTEIN P53;

APOPTOSIS; CANCER RESISTANCE; DRUG RESPONSE; IONIZING RADIATION; LYMPHOMA CELL; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; TRANSGENE;

EID: 0034935347     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1054/drup.2001.0187     Document Type: Short Survey

References (23)

1. Drug target interactions: Only the first step in the commitment to a programmed cell death
2. Programmed cell death (apoptosis) and response to anticancer drugs
3. Apoptosis, p53, and tumor cell sensitivity to anticancer agents
4. Genetic analysis of chemoresistance in primary murine lymphomas
5. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
6. Activation of programmed cell death by anticancer agents: Cisplatin as a model system
7. Apoptosis in cancer therapy: Crossing the threshold
8. BCL-2 expression delays drug-induced apoptosis but does not increase clonogenic survival after drug treatment in HeLa cells
9. p53-dependent apoptosis suppresses tumor growth and progression in vivo
10. Tumor cells utilize multiple pathways to down-modulate apoptosis
11. Flp-mediated tissue-specific inactivation of the retinoblastoma tumor suppressor gene in the mouse
12. L and Bax by tumor microenvironmental factors
13. L mediate tumor cell resistance to chemotherapy
14. Effects of the multidrug transporter P-glycoprotein on cellular responses to ionizing radiation
15. Clinical implications of p53 mutations
16. p53 status and the efficacy of cancer therapy in vivo
17. A proinflammatory cytokine inhibits p53 tumor suppressor activity
18. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53
19. Bcl-2 family members in childhood acute lymphoblastic leukemia: Relationships with features at presentation, in vitro and in viva drug response and long-term clinical outcome
20. Genetic determinants of response to chemotherapy in transgenic mouse mammary and salivary tumors
21. Sensitivity to myc-induced apoptosis is retained in spontaneous and transplanted lymphomas of CD2-mycER™ mice
22. Genetic polymorphism in MDR-I: A tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors
23. Apoptosis and therapy